Candel Therapeutics, Inc. CADL Fair Value Adjustment Of Warrants
Fair Value Adjustment Of Warrants at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FairValueAdjustmentOfWarrants.
The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Candel Therapeutics, Inc.'s fair value adjustment of warrants.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Candel Therapeutics, Inc.'s fair value adjustment of warrants?
- Candel Therapeutics, Inc. (CADL) reported fair value adjustment of warrants of -$7.64M in Q1 2026.
- How has Candel Therapeutics, Inc.'s fair value adjustment of warrants changed year-over-year?
- Candel Therapeutics, Inc.'s fair value adjustment of warrants increased by 48.6% year-over-year, from -$14.88M to -$7.64M.
- What does fair value adjustment of warrants mean?
- This reflects the periodic change in the estimated fair value of outstanding warrant liabilities, which are often revalued based on stock price volatility and time to expiration. As a non-cash item, it highlights the impact of financial instrument valuation fluctuations on the company's reported earnings.